Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03058744 · ClinicalTrials.gov registry record · Phase 1
Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis
A Phase 1 study of Psoriasis, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 12
- Study locations
NCT03058744 is a Phase 1 study of Psoriasis that has completed, run by Bausch Health Americas. The registered enrollment target is 94 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (81% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT03058744, a Phase 1 study of Psoriasis, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 12
- Study locations
Study Summary
Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis.
Conditions Studied
Interventions
- DRUG IDP-118 Lotion
- DRUG HP Monad Lotion
- DRUG Ultravate Cream
- DRUG Tazorac Cream
Study Locations (12)
California
- Valeant Site 12 - Anaheim
- Valeant Site 05 - Encino
- Valeant Site 01 - San Diego
- Valeant Site 07 - Santa Rosa
Florida
- Valeant Site 10 - Orange Park
- Valeant Site 09 - Sanford
Texas
- Valeant Site 03 - Austin
- Valeant Site 02 - Katy
Georgia
- Valeant Site 08 - Atlanta
Indiana
- Valeant Site 04 - Plainfield
New York
- Valeant Site 06 - New York
Pennsylvania
- Valeant Site 11 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03058744
The ClinicalTrials.gov registry entry for NCT03058744 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (81% lower). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which IDP-118 Lotion is the first listed.
NCT03058744 reports 12 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT03058744 about?
NCT03058744 is a clinical study titled "Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis". Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis.
What is the current status of trial NCT03058744?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2015-04. Estimated completion is 2017-01.
What conditions does trial NCT03058744 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03058744?
The interventions under investigation include: IDP-118 Lotion (DRUG), HP Monad Lotion (DRUG), Ultravate Cream (DRUG), Tazorac Cream (DRUG).
Who is sponsoring clinical trial NCT03058744?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03058744 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.